Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Abstract Text:

Ana Barac,Umberto Campia,Linda A Matuskey,Li Lu,Julio A Panza,

Adipokines are substances produced by the adipose tissue that may play significant roles in the mechanisms contributing to the development of atherosclerosis. Thiazolidinediones have been shown to improve endothelium-dependent vasodilation and to exert multiple antiatherosclerotic effects. This study tested the hypotheses that nondiabetic patients with cardiovascular risk factors have altered levels of adipokines that can be modified by pioglitazone treatment. Eighty patients with hypertension or hypercholesterolemia were in a double-blinded, placebo-controlled, crossover study. In each treatment phase, patients received pioglitazone 45 mg/day or placebo for 8 weeks. Endothelial function studies and biochemical assays were performed at the end of each 8-week treatment period. Twenty-two normal volunteers, matched with patients for age, gender, and body mass index, were recruited as a control group. Compared with controls, placebo-treated patients had lower adiponectin levels (11,160 +/- 763 vs 6,078 +/- 385 ng/ml, p <0.001) and similar plasma leptin levels (21.5 +/- 3.8 vs 16.2 +/- 1.5 ng/ml, p = 0.128) and resistin levels (5.1 +/- 0.4 vs 4.4 +/- 0.2 ng/ml, p = 0.250). In patients, pioglitazone treatment markedly increased adiponectin (+121%, p <0.001) and decreased resistin (-10.5%, p = 0.03). Leptin was not significantly decreased (-7.1%, p = 0.10). In multivariate analysis, pioglitazone-induced changes in endothelial reactivity to acetylcholine were the only significant predictor of increases in adiponectin. In conclusion, in nondiabetic patients with major cardiovascular risk factors, pioglitazone treatment beneficially influences circulating adipokine levels. The relation between the increase in adiponectin levels and the improvement in endothelial vasodilator activity suggests a mechanistic link between vascular effects and adiponectinemia.

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Publishing Authors By Initials

A Barac,U Campia,LA Matuskey,L Lu,JA Panza,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The American journal of cardiology

VOLUME: 101

Page Numbers: 980-5

Journal Abbreviation: Am. J. Cardiol.

ISSN: 0002-9149

DAY: 1

MONTH: Apr

YEAR: 2008

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 207277

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.

AFFILIATION: Cardiovascular Research Institute at the Washington Hospital Center, Washington, DC.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension Related Publications

• Analysis of individual items of mini-mental state examination in discrimination between normal and demented subjects.
• Beyond coronary artery disease: rosuvastatin in older patients with ischemic systolic heart failure.
• Dietary Fatty acids, age-related cognitive decline, and mild cognitive impairment.
• Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
• Flavanol-rich cocoa a promising new dietary intervention to reduce cardiovascular risk in type 2 diabetes?
• Interleukin 6 variable number of tandem repeats (VNTR) gene polymorphism in centenarians.
• Lifestyle-related factors, alcohol consumption, and mild cognitive impairment.
• Milk-of-calcium in breast microcysts with adjacent malignancy.
• Patients with end-stage renal disease and acute myocardial infarction have poor short-term outcomes despite modern cardiac intensive care.
• Short arm of chromosome 11 and sporadic Alzheimer's disease: Catalase and cathepsin D gene polymorphisms.